Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis

Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis

(2020) Franziska Herster et al.   Nature Communications

Comparison of Biologics and Oral Treatments for Plaque Psoriasis

(2020) April W. Armstrong et al.   JAMA Dermatology

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial

(2020) Seth B. Forman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Hidradenitis suppurativa

(2020) Robert Sabat et al.   Nature Reviews Disease Primers

Persistence and Effectiveness of Non-Biologic Systemic Therapies for Moderate-Severe Psoriasis in Adults: a Systematic Review

(2019) K.J. Mason et al.   BRITISH JOURNAL OF DERMATOLOGY

Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort

(2019) Alexander Egeberg et al.   BMJ Open

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

(2019) Hervé Bachelez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes

(2019) Sonja Moos et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IL-17E (IL-25) enhances innate immune responses during skin inflammation

(2019) Luisa Senra et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Brodalumab for the treatment of plaque psoriasis: up-to-date

(2019) Kristen M. Beck et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study

(2019) Youssef A Elnabawi et al.   CARDIOVASCULAR RESEARCH

Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

(2019) Irina Gasslitter et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

(2019) Stefan Schreiber et al.   ANNALS OF THE RHEUMATIC DISEASES

Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease

(2019) Christopher Ma et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

(2019) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR

(2019) Denis A. Mogilenko et al.   CELL

Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study

(2019) Matteo Megna et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data

(2019) Sree S. Kolli et al.   Expert Opinion On Drug Safety

The IL-23/IL-17 pathway in human chronic inflammatory diseases—new insight from genetics and targeted therapies

(2019) Elisabetta Bianchi et al.   GENES AND IMMUNITY

The IL-17 Family of Cytokines in Health and Disease

(2019) Mandy J. McGeachy et al.   IMMUNITY

The Immunobiology of the Interleukin-12 Family: Room for Discovery

(2019) Elia D. Tait Wojno et al.   IMMUNITY

T cell pathology in skin inflammation

(2019) Robert Sabat et al.   Seminars in Immunopathology

Psoriasis treat to target: defining outcomes in psoriasis using data from a real world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR )

(2019) S.K. Mahil et al.   BRITISH JOURNAL OF DERMATOLOGY

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

(2019) Stephen T. Wrobleski et al.   JOURNAL OF MEDICINAL CHEMISTRY

Incidence and prevalence of psoriasis in Israel between 2011 and 2017

(2019) Y. Schonmann et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

(2019) Kristian Reich et al.   LANCET

Autoreactive T-Lymphocytes in Inflammatory Skin Diseases

(2019) Wolf-Henning Boehncke et al.   Frontiers in Immunology

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

(2019) Kristian Reich et al.   LANCET

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response

(2019) Laura M. Sawyer et al.   PLoS One

Emerging Topical and Systemic JAK Inhibitors in Dermatology

(2019) Farzan Solimani et al.   Frontiers in Immunology

Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis

(2018) C. Ryan et al.   BRITISH JOURNAL OF DERMATOLOGY

Guselkumab for the treatment of psoriasis

(2018) Matteo Megna et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials

(2018) Lian Cui et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical Outcome

(2018) Irène Gallais Sérézal et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials

(2018) Mark G. Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

(2018) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

(2018) Atul Deodhar et al.   LANCET

HLA-C*06:02-independent, gender-related association of PSORS1C3 and PSORS1C1/CDSN single-nucleotide polymorphisms with risk and severity of psoriasis

(2018) Andrzej Wiśniewski et al.   MOLECULAR GENETICS AND GENOMICS

The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells

(2018) C. Enerbäck et al.   Scientific Reports

Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis

(2018) Lipeng Tang et al.   Frontiers in Immunology

IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis

(2018) Charlie Bridgewood et al.   Frontiers in Immunology

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

(2018) Dominique Baeten et al.   ANNALS OF THE RHEUMATIC DISEASES

Candidate long-range regulatory sites acting on the IL17 pathway genes TRAF3IP2 and IL17RA are associated with psoriasis

(2018) Joanne Nititham et al.   EXPERIMENTAL DERMATOLOGY

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

(2018) Kenneth B Gordon et al.   LANCET

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

(2018) Kim Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

OUP accepted manuscript

(2018)   RHEUMATOLOGY

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond

(2018) Nicolo Costantino Brembilla et al.   Frontiers in Immunology

Efficacy and safety of switching to ixekizumab in secukinumab nonresponder psoriatic patients: results from a multicenter experience

(2018) A. Conti et al.   BRITISH JOURNAL OF DERMATOLOGY

Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks

(2018) Esther von Stebut et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Biological Effects of IL-26 on T Cell–Mediated Skin Inflammation, Including Psoriasis

(2018) Takumi Itoh et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The IL-1 pathway is hyperactive in Hidradenitis suppurativa and contributes to skin infiltration and destruction

(2018) Ellen Witte-Händel et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study

(2018) G. Deza et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

(2018) Philip Mease et al.   LANCET

Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients

(2018) Matthew T. Patrick et al.   Nature Communications

Association of Psoriasis With Inflammatory Bowel Disease

(2018) Yun Fu et al.   JAMA Dermatology

IL-17F regulates psoriasis-associated genes through IκBζ

(2017) Trine Bertelsen et al.   EXPERIMENTAL DERMATOLOGY

Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling

(2017) Nick Dand et al.   HUMAN MOLECULAR GENETICS

Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones

(2017) Tiago R. Matos et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

European consensus statement on phenotypes of pustular psoriasis

(2017) A.A. Navarini et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Richard B Warren et al.   LANCET

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target

(2017) Satveer K. Mahil et al.   Science Translational Medicine

Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants

(2017) Lam C. Tsoi et al.   Nature Communications

Ultraviolet B Inhibits IL-17A/TNF-α-Stimulated Activation of Human Dermal Fibroblasts by Decreasing the Expression of IL-17RA and IL-17RC on Fibroblasts

(2017) Li Yin et al.   Frontiers in Immunology

Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

(2017) Ya-Chu Tsai et al.   Therapeutic Advances in Musculoskeletal Disease

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

(2016) V.J. Ludbrook et al.   BRITISH JOURNAL OF DERMATOLOGY

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

(2016) Robert Bissonnette et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Characterization of TNF-α– and IL-17A–Mediated Synergistic Induction of  DEFB4 Gene Expression in Human Keratinocytes through IκBζ

(2016) Claus Johansen et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis

(2016) Luisa Senra et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Defining the functional binding sites of interleukin 12 receptor β1 and interleukin 23 receptor to Janus kinases

(2016) Doreen M. Floss et al.   MOLECULAR BIOLOGY OF THE CELL

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity

(2016) C. A. Dendrou et al.   Science Translational Medicine

IL-12 protects from psoriasiform skin inflammation

(2016) Paulina Kulig et al.   Nature Communications

Psoriasis

(2016) Jacqueline E. Greb et al.   Nature Reviews Disease Primers

Melanocyte antigen triggers autoimmunity in human psoriasis

(2015) Akiko Arakawa et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Psoriasis

(2015) Wolf-Henning Boehncke et al.   LANCET

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

(2015) Hervé Bachelez et al.   LANCET

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

(2015) Sanjaya Singh et al.   mAbs

Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments

(2015) John Foerster et al.   Nanomedicine

Clinical improvement in psoriasis with specific targeting of interleukin-23

(2015) Tamara Kopp et al.   NATURE

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells

(2015) Emmanuella Guenova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunology of Psoriasis

(2014) Michelle A. Lowes et al.   Annual Review of Immunology

IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage

(2014) G. L. Stritesky et al.   JOURNAL OF IMMUNOLOGY

Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis

(2014) S. Cheuk et al.   JOURNAL OF IMMUNOLOGY

IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis

(2014) Ellen Witte et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Necrosis Factor Receptor Signaling in Keratinocytes Triggers Interleukin-24-Dependent Psoriasis-like Skin Inflammation in Mice

(2013) Snehlata Kumari et al.   IMMUNITY

Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation

(2013) A. Johnston et al.   JOURNAL OF IMMUNOLOGY

Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ ILC3 in Psoriasis

(2013) Federica Villanova et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Therapeutic opportunities of the IL-22–IL-22R1 system

(2013) Robert Sabat et al.   NATURE REVIEWS DRUG DISCOVERY

An In-Depth Characterization of the Major Psoriasis Susceptibility Locus Identifies Candidate Susceptibility Alleles within an HLA-C Enhancer Element

(2013) Alex Clop et al.   PLoS One

IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis

(2013) K. Wolk et al.   Science Translational Medicine

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

(2012) Lam C Tsoi et al.   NATURE GENETICS

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

(2011) Kamran Ghoreschi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis

(2011) Yijun Carrier et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis

(2011) Trilokraj Tejasvi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5

(2011) Xiang-Ping Yang et al.   NATURE IMMUNOLOGY

The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans

(2011) Paola Di Meglio et al.   PLoS One

Angiogenesis drives psoriasis pathogenesis

(2010) Regina Heidenreich et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa

(2010) K. Wolk et al.   JOURNAL OF IMMUNOLOGY

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

(2010) Robert Bissonnette et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Generation of pathogenic TH17 cells in the absence of TGF-β signalling

(2010) Kamran Ghoreschi et al.   NATURE

A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1

(2010) Amy Strange et al.   NATURE GENETICS

The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis

(2009) Kerstin Wolk et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis

(2009) Erin G. Harper et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not

(2009) Kerstin Wolk et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21

(2009) Xue-Jun Zhang et al.   NATURE GENETICS

Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways

(2009) Rajan P Nair et al.   NATURE GENETICS

Selectivity and therapeutic inhibition of kinases: to be or not to be?

(2009) Kamran Ghoreschi et al.   NATURE IMMUNOLOGY

Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic Cells

(2008) Lisa C. Zaba et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY